Phosphomannose Isomerase Inhibitors Improve N-glycosylation in Selected Phosphomannomutase-deficient Fibroblasts

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2011 Sep 28

PMID 21949237

Citations 28

Authors

Vandana Sharma

Mie Ichikawa

Ping He

David A Scott

Yalda Bravo

Russell Dahl

Bobby G Ng

Nicholas D P Cosford

Hudson H Freeze

Affiliations

Soon will be listed here.

Abstract

Congenital disorders of glycosylation (CDG) are rare genetic disorders due to impaired glycosylation. The patients with subtypes CDG-Ia and CDG-Ib have mutations in the genes encoding phosphomannomutase 2 (PMM2) and phosphomannose isomerase (MPI or PMI), respectively. PMM2 (mannose 6-phosphate → mannose 1-phosphate) and MPI (mannose 6-phosphate ⇔ fructose 6-phosphate) deficiencies reduce the metabolic flux of mannose 6-phosphate (Man-6-P) into glycosylation, resulting in unoccupied N-glycosylation sites. Both PMM2 and MPI compete for the same substrate, Man-6-P. Daily mannose doses reverse most of the symptoms of MPI-deficient CDG-Ib patients. However, CDG-Ia patients do not benefit from mannose supplementation because >95% Man-6-P is catabolized by MPI. We hypothesized that inhibiting MPI enzymatic activity would provide more Man-6-P for glycosylation and possibly benefit CDG-Ia patients with residual PMM2 activity. Here we show that MLS0315771, a potent MPI inhibitor from the benzoisothiazolone series, diverts Man-6-P toward glycosylation in various cell lines including fibroblasts from CDG-Ia patients and improves N-glycosylation. Finally, we show that MLS0315771 increases mannose metabolic flux toward glycosylation in zebrafish embryos.

Citing Articles

Borrelial phosphomannose isomerase as a cell surface localized protein that retains enzymatic activity and promotes host-pathogen interaction.

Dutta S, Rana V, Backstedt B, Shakya A, Kitsou C, Yas O mBio. 2025; 16(3):e0360924.

PMID: 39932273 PMC: 11898738. DOI: 10.1128/mbio.03609-24.

AAV9-based gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG).

Zhong M, Balakrishnan B, Guo A, Lai K Mol Genet Metab Rep. 2023; 38:101035.

PMID: 38130891 PMC: 10733668. DOI: 10.1016/j.ymgmr.2023.101035.

Glycolytic interference blocks influenza A virus propagation by impairing viral polymerase-driven synthesis of genomic vRNA.

Kleinehr J, Schofbanker M, Daniel K, Gunl F, Mohamed F, Janowski J PLoS Pathog. 2023; 19(7):e1010986.

PMID: 37440521 PMC: 10343032. DOI: 10.1371/journal.ppat.1010986.

Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.

Woodley K, Dillingh L, Giotopoulos G, Madrigal P, Rattigan K, Philippe C Nat Commun. 2023; 14(1):2132.

PMID: 37059720 PMC: 10104861. DOI: 10.1038/s41467-023-37652-0.

Mannose and phosphomannose isomerase regulate energy metabolism under glucose starvation in leukemia.

Saito Y, Kinoshita M, Yamada A, Kawano S, Liu H, Kamimura S Cancer Sci. 2021; 112(12):4944-4956.

PMID: 34533861 PMC: 8645730. DOI: 10.1111/cas.15138.

References

Grunewald S . The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta. 2009; 1792(9):827-34. DOI: 10.1016/j.bbadis.2009.01.003. View

Panneerselvam K, Freeze H . Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J Clin Invest. 1996; 97(6):1478-87. PMC: 507208. DOI: 10.1172/JCI118570. View

Proudfoot A, Payton M, Wells T . Purification and characterization of fungal and mammalian phosphomannose isomerases. J Protein Chem. 1994; 13(7):619-27. DOI: 10.1007/BF01890460. View

Kjaergaard S, Skovby F, Schwartz M . Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Eur J Hum Genet. 1998; 6(4):331-6. DOI: 10.1038/sj.ejhg.5200194. View

Schollen E, Kjaergaard S, Legius E, Schwartz M, Matthijs G . Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur J Hum Genet. 2000; 8(5):367-71. DOI: 10.1038/sj.ejhg.5200470. View

Nanchen A, Fuhrer T, Sauer U . Determination of metabolic flux ratios from 13C-experiments and gas chromatography-mass spectrometry data: protocol and principles. Methods Mol Biol. 2006; 358:177-97. DOI: 10.1007/978-1-59745-244-1_11. View

Freeze H . Genetic defects in the human glycome. Nat Rev Genet. 2006; 7(7):537-51. DOI: 10.1038/nrg1894. View

Haeuptle M, Hennet T . Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum Mutat. 2009; 30(12):1628-41. DOI: 10.1002/humu.21126. View

Haeuptle M, Welti M, Troxler H, Hulsmeier A, Imbach T, Hennet T . Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid. J Biol Chem. 2010; 286(8):6085-91. PMC: 3057845. DOI: 10.1074/jbc.M110.165795. View

10.

van Winden W, Wittmann C, Heinzle E, Heijnen J . Correcting mass isotopomer distributions for naturally occurring isotopes. Biotechnol Bioeng. 2002; 80(4):477-9. DOI: 10.1002/bit.10393. View

11.

Price N . Acylic sugar derivatives for GC/MS analysis of 13C-enrichment during carbohydrate metabolism. Anal Chem. 2004; 76(22):6566-74. DOI: 10.1021/ac049198m. View

12.

Vega A, Perez-Cerda C, Abia D, Gamez A, Briones P, Artuch R . Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis. 2011; 34(4):929-39. DOI: 10.1007/s10545-011-9328-2. View

13.

Gracy R, NOLTMANN E . Studies on phosphomannose isomerase. I. Isolation, homogeneity measurements, and determination of some physical properties. J Biol Chem. 1968; 243(11):3161-8. View

14.

Vuillaumier-Barrot S, Hetet G, Barnier A, Dupre T, Cuer M, de Lonlay P . Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients. J Med Genet. 2000; 37(8):579-80. PMC: 1734666. DOI: 10.1136/jmg.37.8.579. View

15.

DeRossi C, Bode L, A Eklund E, Zhang F, Davis J, Westphal V . Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality. J Biol Chem. 2005; 281(9):5916-27. DOI: 10.1074/jbc.M511982200. View

16.

A Eklund E, Merbouh N, Ichikawa M, Nishikawa A, Clima J, Dorman J . Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts. Glycobiology. 2005; 15(11):1084-93. DOI: 10.1093/glycob/cwj006. View

17.

Portnoy V, Scott D, Lewis N, Tarasova Y, Osterman A, Palsson B . Deletion of genes encoding cytochrome oxidases and quinol monooxygenase blocks the aerobic-anaerobic shift in Escherichia coli K-12 MG1655. Appl Environ Microbiol. 2010; 76(19):6529-40. PMC: 2950451. DOI: 10.1128/AEM.01178-10. View

18.

Sharma V, Freeze H . Mannose efflux from the cells: a potential source of mannose in blood. J Biol Chem. 2011; 286(12):10193-200. PMC: 3060472. DOI: 10.1074/jbc.M110.194241. View

19.

Freeze H, Sharma V . Metabolic manipulation of glycosylation disorders in humans and animal models. Semin Cell Dev Biol. 2010; 21(6):655-62. PMC: 2917643. DOI: 10.1016/j.semcdb.2010.03.011. View

20.

Dahl R, Bravo Y, Sharma V, Ichikawa M, Dhanya R, Hedrick M . Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem. 2011; 54(10):3661-8. PMC: 3437750. DOI: 10.1021/jm101401a. View